Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504036 | 0.94 | MAP3K8 (0.33) | HTR2CSLC6A4KRASMAP3K8RXRA | |
| SCHEMBL6504626 | 0.91 | MAP3K8 (0.41) | KRASMAP3K8 | |
| SCHEMBL6500744 | 0.91 | MAP3K8 (0.34) | HTR2CSLC6A4KRASMAP3K8RXRA | |
| SCHEMBL6502580 | 0.91 | KRAS (0.33) | HTR2CSLC6A4KRASMAP3K8RXRA | |
| SCHEMBL12886334 | 0.89 | MAP3K8 (0.41) | KRASMAP3K8 | |
| SCHEMBL5847254 | 0.89 | MAP3K8 (0.36) | HTR2CSLC6A4KRASMAP3K8 | |
| SCHEMBL6505107 | 0.89 | MAP3K8 (0.42) | KRASMAP3K8RXRARXRBRXRG | |
| SCHEMBL6507148 | 0.89 | MAP3K8 (0.40) | KRASMAP3K8RXRARXRBRXRG | |
| SCHEMBL5846701 | 0.88 | CDK1 (0.43) | HTR2CSLC6A4MAP3K8 | |
| SCHEMBL6506250 | 0.87 | KRAS (0.34) | HTR2CSLC6A4KRASMAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | HTR2C 3032/4885SLC6A4 4689/4885KRAS 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.